| HOME >> MEDICINE >> TECHNOLOGY |
Figure 19: Bone Metastases Therapeutics Market, The UK, Forecasts ($m), 2010–2017 29
Figure 20: Bone Metastases Therapeutics Market, Japan, Revenue ($m), 2005–2010 30
Figure 21: Bone Metastases Therapeutics Market, Japan, Forecasts ($m), 2010–2017 31
Figure 22: Opportunity and Unmet Need in the Bone Metastases Therapeutics Market 33
Figure 23: Bone Metastases Therapeutics – Strategic Competitor Assessment, 2010 34
Figure 24: Bone Metastases Therapeutics – Pipeline by Phase of Development, 2010 38
Figure 25: Bone Metastases Therapeutics – Technology Trends Analytics Framework, 2010 40
Figure 26: Bone Metastases Therapeutics – Technology Trends Analytics Framework – Description, 2010 40
Figure 27: Bone Metastases Therapeutics – Pipeline by Mechanism of Action, 2010 41
Figure 28: Bone Metastases Therapeutics – Clinical Trials by Country, 2011 45
Figure 29: Bone Metastases Therapeutics - Clinical Trials by Phase, 2011 46
Figure 30: Bone Metastases Therapeutics - Clinical Trials by Status, 2011 47
Figure 31: Bone Metastases Therapeutics - Overall Sponsors, 2011 48
Figure 32: Bone Metastases Therapeutics - Prominent Sponsors, 2011 48
Figure 33: Bone Metastases Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 50
Figure 34: Bone Metastases Therapeutics Market, Drivers and Restraints, 2011 51
Figure 35: Implications for Future Market Competition in Bone Metastases, 2011 52
Figure 36: Bone Metastases Therapeutics – Pipeline by Company, 2011 53
Figure 37: GlobalData Market Forecasting Model 79Novartis AG
Amgen Inc.
Bayer AG
Algeta ASA
Merrion Pharmaceuticals Plc
To order this report:
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |